Immune-Pathogenesis of Myeloma.
Hematol Oncol Clin North Am
; 38(2): 281-291, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38195307
ABSTRACT
This research indicates that monoclonal gammopathy of undetermined significance (MGUS) and myeloma may stem from chronic immune activation and inflammation, causing immune dysfunction and spatial immune exclusion. As the conditions progress, a shift toward myeloma involves ongoing immune impairment, affecting both innate and adaptive immunity. Intriguingly, even in advanced myeloma stages, susceptibility to immune effector cells persists. This insight highlights the intricate interplay between immune responses and the development of these conditions, paving the way for potential therapeutic interventions targeting immune modulation in the management of MGUS and myeloma.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Gamopatia Monoclonal de Significância Indeterminada
/
Mieloma Múltiplo
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article